Polyrizon Ltd. (Nasdaq: PLRZ), a biotechnology company specializing in intranasal drug delivery systems, has announced promising preclinical results from its recent study on the Trap & Target (T&T) platform, an innovative hydrogel-based formulation. Conducted in collaboration with the University of Parma, Italy, the study demonstrated successful targeted deposition in the upper nasal cavity, crucial for central nervous system $(CNS)$ drug delivery. The hydrogel formulation achieved over 60% preferential accumulation in areas favorable for nose-to-brain transport, indicating potential applications for CNS-related conditions such as opioid overdose and epileptic seizures. Polyrizon plans to continue preclinical development and initiate safety studies to further validate these findings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.